Camilla Fuchs Andersen

MD, currently employed as a PhD student at Herlev-Gentofte hospital

[AmericanHeartJ @AmericanHeartJ]

OPEN ACCESS: Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
https://t.co/FaiBIEEGki
#Cardiology

[Empire Prevent @EmpirePrevent]

The Empire Prevent trial program marks the first step towards elucidating the potential of SGLT2 inhibition for HF prevention 🫀🫀

Further reading: https://t.co/Cg7MW1K1CP

@CardResearchOuh @HGHHjerte @RigsHeart @jhempelheart @FuchsAndersen @mortschou

[Empire Prevent @EmpirePrevent]

Empire Prevent 🩵🩷 includes patients in Odense @CardResearchOuh and Copenhagen @HGHHjerte. We greatly appreciate our collaboration with @SDCOdense and @RigsHeart 🩵🩷

[Empire Prevent @EmpirePrevent]

Patient #100 randomized in Empire Prevent

Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial.

Collaboration between @CardResearchOuh and @HGHHjerte.

[Johan Larsson @_JohanLarsson]

#HeartFailureAwarenessDays 2022!

Information campaign today at Herlev Hospital.

Conversations with visitors and employees. Focus on contacting your doctor and getting examined in case of suspect symptoms.

#HFAESC @HFA_President
@NinaNouhravesh @FuchsAndersen Lærke Nelson